Should CTCs Guide Treatment Choice in HR+, HER2 – Breast Cancer? Should CTCs Guide Treatment Choice in HR+, HER2 – Breast Cancer?

Trial results suggest circulating tumor cell (CTC) counts may be a reliable biomarker for guidingfirst-line treatment in patients with HR+, HER2 – metastatic breast cancer.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news